Opinion|Videos|September 10, 2024
Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS
Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For patients with higher-risk myelodysplastic syndromes (MDS), what are some of the primary challenges in conducting research and developing novel therapies for this patient population?
- How do social support and logistical factors, such as the ability to access clinics for extended periods for injectable hypomethylating agents (HMAs), affect treatment adherence and outcomes in patients with higher-risk MDS?
- Given that HMAs are the backbone of treatment for higher-risk MDS, how do oral options such as decitabine-cedazuridine and other emerging therapies address the need for more convenient administration while maintaining efficacy?
Advertisement
Related to this article
The 2026 meeting in Denver features more than 265 hours of programming, real-world MASH treatment data, and late-breaking results in rare liver diseases.
In 299 patients, more involved compartments were linked to higher complication risk after one-stage resection; 14.4% had documented recurrence.
A cranberry supplement was tied to greater OAB symptom score reductions than placebo in a 25-woman pilot trial, but urobiome findings were unconfirmed.
In a matched analysis of Epic COSMOS records, acoramidis was tied to an 18% lower composite risk and about 25% lower hospitalization risk.
A runner's death at the NYC marathon highlights how heat, dehydration, illness, drugs, and genetics can raise exertional rhabdomyolysis risk.
Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.
In an insured population with advanced lung cancer, clinical trial participants had lower or similar total health care costs compared with nonparticipants.
ALLEGRO extension news shows Litfulo (ritlecitinib) delivers durable hair regrowth in severe alopecia areata after 3 years.
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
3
Cranberry Supplement Tied to Greater OAB Score Reductions in Pilot Trial
4
Disease Extent Linked to Complications After Deep Endometriosis Surgery
5